Abstract
Introduction
Currently, men who are diagnosed with early prostate cancer face the dilemma of whether to undergo active surveillance or have treatment directed to the whole prostate, with surgery or radiotherapy [1, 2] . Active surveillance involves repeated biopsies and frequent prostate-specific antigen (PSA) testing, often results in anxiety, and cross-over to active therapy occurs with or without evidence of progression [3] . Whole gland treatment is associated with a known set of side-effects, that most men wish to avoid [4] . The increasing precision of modern diagnostics is permitting a more refined characterisation of risk and has introduced the relatively novel attribute of tumour location [5, 6] . This transition has permitted the substitution of an anatomical target for therapy -in other words the contour of the prostate -to one that is defined by the location and burden of the tumour. The result is tissue preserving or focal therapy [7] , an approach that has proved beneficial in most other solid organs. tissue [8] . Phase II studies demonstrated that WST09 effectively produced ablation in targeted volumes of prostate tissue. However, intraoperative hypotension occurred in association with cardiovascular effects that were thought to be linked to the solubilizing excipient Cremophor ® [9] . In order to avoid these side effects, the hydrophilic derivative WST11 was developed, which is soluble in aqueous solutions, so that Cremophor ® is not required [10] . Preclinical studies in several animal models have shown that treatment with WST11 leads to occlusion of the entire tumour vasculature within a few minutes of treatment, leading to tumour ablation [11, 12, 13] .
The present paper reports the findings from a Phase II, prospective, multicentre, open-label, single intravenous (IV) dose study of WST11-VTP, which was designed to determine the optimal drug concentration and light dose parameters to achieve prostate ablation in men with early prostate cancer. The primary efficacy criteria were the histological assessment of a 6-month biopsy, and assessment of volume of hypoperfusion on gadolinium enhanced magnetic resonance imaging (MRI) scan at 7 days. Safety and quality of life were also assessed.
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Patients and methods
Patients
Men (>18 years of age) diagnosed with low-risk prostate cancer, who were suitable for active surveillance, were invited to take part in the study. The main exclusion criteria were: Prior or current treatment for their cancer, including hormonal manipulation (excluding 5-alpha reductase inhibitors) or androgen supplements in the last 6 months, radiation therapy, chemotherapy, or trans-urethral resection of the prostate and the use of any photosensitising medication for 1 month before and 1 week after the VTP procedure. In men diagnosed by transrectal ultrasound scan (TRUS) guided biopsy, the histological entry criterion was limited to Gleason pattern 3+3. For men diagnosed by transperineal template guided biopsy, secondary Gleason pattern 4 was permitted provided that it was low burden (<3 cores positive per lobe and </=3mm maximum cancer core length). No other restrictions were placed on the number of positive cores present at baseline. The upper limit of PSA prior to consent was 10ng/ml, with a maximum clinical stage of T2b
(radiological stage T2c acceptable).
Ethics statement
The study was conducted within 9 university hospital centres in Europe (France, the Netherlands and United Kingdom) and Canada.
The protocol, all protocol amendments, the proposed Patient Informed Consent Document were submitted to the following Independent Ethics
Committees or Institutional Review Boards for approval. All patients gave signed informed consent to participate before any study-related activities were performed.
Study design
This was a multicentre, phase II, open-label, single IV dose escalation, 6-month, clinical trial, designed to determine the optimal treatment conditions necessary to achieve prostate cancer ablation. Patients were followed for 6 months post-treatment. MRIs of the prostate were assessed 1 week, 3
Accepted Article months and 6 months after the VTP procedure, and a prostate biopsy was undertaken at 6 months post-procedure. Preclinical data had shown predictable ablation volumes using 2mg/kg of WST11 with a light energy dose of 200J/cm [15] . These were the treatment parameters for the first 3 men in the study. The drug dose escalation plan comprised an increase to 4 and 6mg/kg, contingent on the effects on prior patients. The decision to escalate the dose was based on the volume of hypoperfusion (treatment effect) on the Day 7 MRI and any AEs reported to the Data Safety Monitoring Board.
The procedure was performed under general anaesthesia. The procedure has been previously described in detail [9, 10] . A transperineal template (Mick This phase was precisely monitored by continuous clinical surveillance and was stopped in the event of occurrence of a significant AE. The total duration of the whole procedure was about 2 hours (including anaesthesia, fibre placement and illumination with the laser light). At the end of the illumination, the laser was turned off and the fibres withdrawn from the prostate.
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A urinary catheter was left in situ until the next morning. The patient was required to wear protective eye wear and stay in low level light for the first hours after the treatment.
Efficacy and Safety Criteria
The primary efficacy criterion was the result of a 12-core prostate biopsy, 6 months after VTP. Success was defined as a negative biopsy in the treated lobe(s). 
Statistical Methods
Descriptive statistics (n, mean, standard deviation (SD), median, minimum and maximum) were calculated for quantitative variables; frequency count by category was given for qualitative variables. Confidence intervals were given where appropriate. If not otherwise stated, all statistical tests were 2-sided and at the 5% level of significance, and provided 95% confidence.
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The only statistical inference performed was the 1-sided binomial exact test for the proportion of patients with negative biopsy assessment at Month 6.
This study served to generate hypotheses on the primary efficacy objective for a future phase III clinical study. A significant difference between the proportion under the null hypothesis and the alternative of at least 25% was seen as clinically relevant.
Results
Forty-two men were enrolled in the study with 4 excluded from the final efficacy analysis (Figure 2 ). The baseline characteristics of the 42 enrolled men are shown in Table 1 . Two patients underwent anaesthesia for the procedure, but did not receive the drug or light dose: one patient due to a rectal abnormality which precluded satisfactory ultrasound probe placement, and another due to ECG changes suspicious for ischaemia which were seen after the start of the anaesthesia. Two additional patients underwent the full VTP procedure, but could not be evaluated for efficacy: one man had the incorrect lobe treated and the other was staged as T3a at Month 6, which on central radiologist review was confirmed as being present and missed prior to VTP. The patient in whom the wrong lobe was treated was retreated in the correct lobe after the Month 6 biopsy.
Of the remaining 38 men, 3 men had significant protocol deviations (laser malfunction at the time of treatment, n=2) and administration of an ultrasound contrast agent at the time of the procedure (n=1).
Three patients were treated with WST11 at a dose of 2mg/kg, and 2 patients received the 6mg/kg dose. In the 3 patients treated at the lowest dose, little effect was seen on the Day 7 MRI scans and therefore this dose was deemed to be sub-optimal and no further patients were enrolled at 2mg/kg. The 6mg/kg dose was deemed not suitable for smaller glands, as the treatment effect with 3 fibres appeared to be difficult to maintain within the boundaries of the prostate gland. The 6mg/kg was not evaluated further in this study, but
Accepted Article was evaluated in study PCM203, where it did not result in larger volumes of effect than 4mg/kg. . Thus, the majority of patients (n=33) were dosed at 4mg/kg. All patients who received the WST11 dose were treated with a light energy of 200J/cm, except for 2 patients who received an energy dose of 350J/cm due to a laser malfunction, and were excluded from the final efficacy analysis.
In total, 28 men had a drug dose of 4mg/kg, a light dose of 200J/cm and a minimum of 3 light fibres. An exploratory analysis of these men showed that the light dose per volume of prostate was an important determinant of both treatment effect on contrast enhanced MRI at 1 week, and of 6-month biopsy result. The light density index (LDI) was defined as:
In the 4mg/kg group, 12 men had an LDI of >1, and 16 men an LDI of <1
( Figure 2 ).
Efficacy
6-month biopsy
One patient declined the 6-month biopsy, so 37 biopsies were available for the analysis of the primary efficacy criterion and 38 MRI scans were available for the secondary efficacy criterion.
Of those men who could be evaluated (n=37), 20 had a negative 6-month biopsy (53%), while of those men in the optimal dose-energy group (n=28), 15 had a negative 6-month biopsy (54%) ( Table 2 ). However, when the assessment was limited to men with the optimal treatment conditions (4mg/kg, 200J/cm, LDI >1), the percentage having a negative biopsy increased to 83%
(10/12 men).
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Histopathological analysis of the 6-month biopsies showed that fibrosis was the most frequent histopathological finding after VTP. There were no foci of prostate cancer found within areas of fibrosis.
Gadolinium-enhanced MRI at 1 week
The prostate volume was seen to increase between baseline and 7 days from a mean of 50.7mL to 63.9mL across the 38 men who underwent Day 7 MRI.
This swelling reduced over time, and, combined with fibrosis showed a reduction to a mean volume of 41.8mL at 3 months (n=36), and 40mL at 6 months (n=33).
The volume of treatment effect was defined as the volume of hypoperfusion at Day 7 divided by the mean of the intended treatment volume at baseline and at 7 days.
In the 38 evaluable men at Day 7, the mean percentage treatment effect (treatment volume/whole prostate volume) was 38%. In men in the 4mg/kg group (n=33), the mean treatment effect was 42%. The majority of these men had had treatment in one lobe only.
In an exploratory analysis of the treated lobe only, the 12 men of the 4mg/kg group with an LDI >1 had a mean treatment volume effect (treatment effect/lobe volume) of 95% versus 59% (p<0.01) in those with an LDI <1. "
The correlation between the LDI and the volume of effect is shown in Figure   3 .
Extraprostatic treatment effect (hypoperfusion outside of the prostate) was observed in 18 of 38 men; in all cases this resolved on follow-up imaging, and was not associated with any clinically evident damage to adjacent organs, fistula or incontinence.
Adverse Events (AEs)
Accepted Article in intensity, with the exception of a melanoma in one of the subjects, which occurred after a number of months. This was considered severe but unrelated to the either the study drug or the procedure.
28/42 patients (66.7%) experienced at least 1 AE related to the technical procedure and 14 patients (33.3%) experienced at least 1 AE related to the study drug. The most common AEs related to the technical procedure were coded to the Reproductive System and Breast Disorders system organ class (SOC) (haematospermia, n=5; erectile dysfunction, n=4; and perineal pain, n=4) and Renal and Urinary Disorders SOC (dysuria, n=9; hematuria, n=8;
and transient urinary retention, n=2). Due to the small number of patients treated at 2 and 6 mg/kg, no analysis can be made on the difference in the level of side effects observed between the treatment doses.
Five patients experienced SAEs of which 3 were related to the technical procedure. Two patients had large extraprostatic necrosis caused by an excessive light dose due to a calibration error; corrective measures were taken immediately to ensure it did not reoccur and both patients recovered without sequelae. One patient had pelvic pain which prolonged hospitalisation by 1 day and was due to the technical procedure. The 2 other SAEs (deep vein thrombosis at 4 months post-procedure and dysuria secondary to a herpetic eruption at 3 days post-procedure) were considered unlikely to be related to the treatment.
Of the 40 patients who received the complete VTP procedure, none withdrew due to AEs.
An analysis of the paper ECG recordings was performed by CardiaBase, an ECG core lab. The results indicated a marked prolongation of the Fridericiacorrected QT (QTcF) interval after the induction of anaesthesia. However, as no further prolongation of the QTcF interval was observed after the injection of WST11, the earlier QTcF changes were deemed due to anaesthetic drugs.
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Quality of Life Questionnaires
Questionnaires were evaluable for 34 patients at baseline and Month 6.
IPSS questionnaire
For all 34 evaluable men, the mean IPSS score for questions 1-7 decreased 
IIEF-5 Questionnaire
For all 34 evaluable men, the mean baseline score was 17.7, falling to 13.8 at invasive, well-tolerated procedure that can be targeted to a pre-determined volume of prostate tissue and administered in an ambulatory setting as a oneoff procedure. This study has contributed to defining the optimal treatment conditions to achieve predictable ablation volumes within the prostate and so provide a method by which clinicians can selectively ablate target volumes of tissue.
More specifically, biopsy data, post-treatment MRI outputs and analysis of the safety data indicate that 4mg/kg WST11, 200J/cm energy and an LDI >1 are probably optimal treatment conditions for prostate ablation using the VTP procedure. In addition the Day-7 MRI result proved to be a good predictor of the 6-month biopsy result, with a mean 95% treatment effect on Day-7 MRI correlating with an 83% negative biopsy rate in men receiving the optimal treatment parameters, compared to a mean treatment effect of 58% and a negative biopsy rate of 31% in the 16 men who received 4mg/kg WST11 with an LDI of <1. This correlation is supported by both preclinical data [14] and those from the post-radiotherapy prostate [9] .
In terms of tolerability and safety, WST11 fared well. No cases of hypotension were reported, which had been a concern with the previous formulation WST09. All adverse events following treatment were mild or moderate, apart Accepted Article from 1 severe case (neoplasm) in the 4mg/kg group, which was considered unrelated to the study medication or procedure. There were 5 SAEs, all in the 4mg/kg group. None were considered related to the study drug, but 3 of the 5 were considered to be related to the study procedure: 2 necrosis events caused by excessive illumination due to device malfunction and 1 of pelvic pain, which was considered serious as it prolonged hospitalisation by 1 day.
Additional unexpected benefits were also recorded. The cohort exhibited a fall in IPSS score that was accompanied by a slight improvement in the quality of life. Erectile function was difficult to assess given that many of the subjects recorded poor or absent baseline function.
Overall there was mild deterioration.
These results need to be considered in the light of some inevitable methodological limitations. First, the number of patients was small as this was an early phase II trial. As it was a dose escalation study, the results of doses other than 4mg/kg were confined to very small samples. A follow-on study (PCM 203) was designed to explore the use of 4mg/kg WST11 and an LDI of 1 in a larger study population. Following completion of PCM 203 a European multicenter phase III study randomizing men to WST11 VTP or active surveillance was set up and has now completed recruitment and randomization of 400 men.
Second, due to the limited sensitivity of TRUS biopsy, a negative biopsy at 6 months post-VTP procedure does not necessarily confirm the absence of tumour. In the context of low-risk prostate cancer on standard TRUS biopsy, 1 in 4 men may have no cancer found on repeat TRUS, although 1 in 4 may be upgraded or upstaged [15] . We considered the use of transperineal template guided biopsy both prior to and following VTP, but decided that the requirement for 3 general anaesthetics in the 6-month study would be too great a burden for the patient. Men who had a template biopsy at baseline (5/41, 12%) were those enrolled in centres with a high volume of men having template biopsy.
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Third, this study had a short follow-up of 6 months, and longer term histological results and patient-reported outcomes are going to be needed in order to establish oncological efficacy.
The attributes of the VTP procedure are very different to existing focal therapy platforms that rely principally on generating extremes of temperature in order to induce coagulative necrosis. These energy sources require an iterative and responsive mode of delivery that is surgeon-driven and is challenging to teach and to learn [16] . WST11 VTP can be planned in advance and the execution is limited to the placement of needles within a sector of the prostate under ultrasound control -a skill that is widely held and easily taught. This, together with the opportunity to be amenable to quality control is a welcome attribute.
This study has permitted a standardisation of the procedure, which is an essential step in the evaluation of any health technologies. It has permitted the design and subsequent approval of a Phase III study in Europe (EUDRACT registration number: 2008-000876-26).
Conclusions
This study has shown that the optimal drug dose, light dose and light density index for prostate ablation using TOOKAD ® Soluble are 4mg/kg WST11 activated by 753nm light at a dose of 200J/cm and a light density index of >1.
These parameters applied in a group of 12 men resulted in treatment effect in 95% of the planned treatment volume and a negative biopsy rate at 6 months of 83%.
Further work to assess this within a European phase III randomized controlled trial comparing WST11 VTP to active surveillance is ongoing, with recruitment of more than 400 men completed.
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Figure Legends * the p value assess the probability of the observed results happening by chance if the null hypothesis (that the treatment has no effect) were true. The proportion of men who would have a negative confirmatory biopsy in the absence of treatment was taken as 40%, to reflect the proportions of men on active surveillance having a negative second biopsy after an initial positive biopsy
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